AU2001287639A1 - Trp8, trp9 and trp10, markers for cancer - Google Patents

Trp8, trp9 and trp10, markers for cancer

Info

Publication number
AU2001287639A1
AU2001287639A1 AU2001287639A AU8763901A AU2001287639A1 AU 2001287639 A1 AU2001287639 A1 AU 2001287639A1 AU 2001287639 A AU2001287639 A AU 2001287639A AU 8763901 A AU8763901 A AU 8763901A AU 2001287639 A1 AU2001287639 A1 AU 2001287639A1
Authority
AU
Australia
Prior art keywords
trp10
trp8
trp9
cancer
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001287639A
Inventor
Ulrich Wissenbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001287639A1 publication Critical patent/AU2001287639A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Abstract

The present invention relates to gene expression in normal cells and cells of malignant tumors and particularly to novel markers associated with cancer, Trp8, Trp9 and Trp10, and the genes encoding Trp8, Trp9 and Trp10. Also provided are vectors, host cells, antibodies, and recombinant methods for producing these human proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating a tumor.
AU2001287639A 2000-07-28 2001-07-18 Trp8, trp9 and trp10, markers for cancer Abandoned AU2001287639A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22151300P 2000-07-28 2000-07-28
US60/221,513 2000-07-28
PCT/EP2001/008309 WO2002010382A2 (en) 2000-07-28 2001-07-18 Trp8, trp9 and trp10, markers for cancer

Publications (1)

Publication Number Publication Date
AU2001287639A1 true AU2001287639A1 (en) 2002-02-13

Family

ID=22828139

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001287639A Abandoned AU2001287639A1 (en) 2000-07-28 2001-07-18 Trp8, trp9 and trp10, markers for cancer

Country Status (8)

Country Link
US (1) US7205108B2 (en)
EP (1) EP1366158B1 (en)
JP (1) JP2004505617A (en)
AT (1) ATE396266T1 (en)
AU (1) AU2001287639A1 (en)
CA (1) CA2417671A1 (en)
DE (1) DE60134178D1 (en)
WO (1) WO2002010382A2 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364867B2 (en) 2000-04-17 2008-04-29 The Mount Sinai School Of Medicine Method of identifying bitter compounds by employing TRP8, a transient receptor potential channel expressed in taste receptor cells
DE10215321A1 (en) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh New nucleic acid encoding Trpp8 splice variants, useful for diagnosis of prostatic cancer, and to screen for diagnostic or therapeutic agents, also related proteins
US20050176010A1 (en) * 2002-04-16 2005-08-11 Bayer Healthcare Ag Regulation of human transient receptor potential channel
JP2005538697A (en) * 2002-04-19 2005-12-22 シエーリング アクチエンゲゼルシャフト A novel prostate tumor-specific promoter
AU2003261710B2 (en) * 2003-01-08 2008-08-14 Nippon Milk Community Co., Ltd. Human calcium transporter 1 gene, screening method of calcium absorption regulating factor, and calcium absorption regulating factor
ES2605443T3 (en) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
CN102973947A (en) 2004-06-01 2013-03-20 健泰科生物技术公司 Antibody-drug conjugates and methods
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US8399201B2 (en) 2005-10-31 2013-03-19 Janssen Pharmaceutica N.V. Polypeptide complex of TRPM8 and calmodulin and its uses thereof
ES2530091T3 (en) 2008-03-19 2015-02-26 Soricimed Biopharma Inc. Peptide compositions for the treatment of cancer by inhibiting the activity of the calcium channel TRPV6
CA2766272C (en) 2009-06-26 2021-02-09 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
AU2011239507B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
SG10201600791TA (en) 2010-06-08 2016-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
JP5889912B2 (en) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド Alaninyl maytansinol antibody conjugate
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
MX350152B (en) 2011-10-14 2017-08-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CN105102068B (en) 2012-10-12 2018-06-01 Adc疗法责任有限公司 Pyrrolobenzodiazepines Zhuo-antibody conjugates
LT2839860T (en) 2012-10-12 2019-07-10 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
NZ707534A (en) 2012-10-12 2018-08-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
JP6270859B2 (en) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ Pyrrolobenzodiazepine-antibody conjugate
DK2906251T3 (en) 2012-10-12 2017-11-20 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22-antibody conjugates
CN110452242A (en) 2012-12-21 2019-11-15 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
CN110627797A (en) 2012-12-21 2019-12-31 麦迪穆有限责任公司 Asymmetric pyrrolobenzodiazepine dimers for the treatment of proliferative and autoimmune diseases
US20160010140A1 (en) 2013-02-28 2016-01-14 Nichirei Biosciences, Inc. Dab-containing substrate kit for dyeing use which is produced using labelling enzyme
CN105307685B (en) 2013-03-13 2019-03-08 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
ES2731779T3 (en) 2013-03-13 2019-11-19 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112016002829A2 (en) 2013-08-12 2017-09-19 Genentech Inc COMPOUND AND PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOUND, PHARMACEUTICAL COMPOSITION, CANCER TREATMENT METHOD, CANCER TREATMENT KIT, DRUG LINKER INTERMEDIATE, CBI DIMER DRUG MOUNT AND COMPOUND
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
PE20161394A1 (en) 2013-12-16 2017-01-06 Genentech Inc PEPTIDOMIMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
CN105828840B (en) 2013-12-16 2020-08-04 基因泰克公司 1- (chloromethyl) -2, 3-dihydro-1H-benzo [ e ] indole dimer antibody-drug conjugate compounds and methods of use and treatment
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド Cysteine engineered antibodies and conjugates
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
CR20170099A (en) 2014-09-17 2017-07-19 Genentech Inc PIRROLOBENZODIAZEPINAS AND CONJUGADOS DE ANTIBERPOS-DISULFURO DE LAS SISAS
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP6671555B2 (en) 2017-02-08 2020-03-25 アーデーセー セラピューティクス ソシエテ アノニム Pyrrolobenzodiazepine antibody conjugate
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3612537T (en) 2017-04-18 2022-08-29 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2018253948A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
EP3638373A1 (en) 2017-06-14 2020-04-22 ADC Therapeutics SA Dosage regimes for the administration of an anti-cd19 adc
EP3668874B1 (en) 2017-08-18 2021-12-22 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
KR20210078502A (en) * 2018-10-18 2021-06-28 펀더멘탈 파마 게엠베하 Novel means of modulating NMDA receptor-mediated toxicity
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885776A (en) * 1997-01-30 1999-03-23 University Of Iowa Research Foundation Glaucoma compositions and therapeutic and diagnositic uses therefor
US5919638A (en) 1996-10-08 1999-07-06 Abbott Laboratories Reagents and methods useful for detecting prostate tumors
HUP0002095A3 (en) 1997-02-25 2002-02-28 Corixa Corp Seattle Compounds for immunotherapy of prostate cancer and methods for their use
US6194152B1 (en) 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
JP2002536966A (en) 1998-12-30 2002-11-05 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド Characterization of the calcium channel family
US6534642B1 (en) * 1999-07-09 2003-03-18 Matthias A. Hediger Compositions corresponding to a calcium transporter and methods of making and using same
WO2001014423A1 (en) 1999-08-19 2001-03-01 Smithkline Beecham P.L.C. Identification of three putative calcium channel vanilrep peptides
AU2074201A (en) 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
KR20030016217A (en) * 2000-01-14 2003-02-26 코릭사 코포레이션 Compositions and methods for the therapy and diagnosis of prostate cancer
US20020072101A1 (en) 2000-01-21 2002-06-13 Gaughan Glen T. Novel human nucleic acid molecules and polypeptides encoding cation channels
AU2001238596A1 (en) * 2000-02-22 2001-09-03 Millennium Pharmaceuticals, Inc. 18607, a novel human calcium channel
WO2001068857A2 (en) 2000-03-15 2001-09-20 Millennium Pharmaceuticals, Inc. 18615 and 48003, human ion channels and uses therefor
EP1294762A2 (en) 2000-06-26 2003-03-26 Millennium Pharmaceuticals, Inc. Human calcium channels (48000; 52920) and uses thereof
AU2001285018A1 (en) * 2000-08-17 2002-02-25 Agensys, Inc. Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
JP2005506033A (en) 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド Prostate cancer diagnostic method, prostate cancer modulator screening composition and method

Also Published As

Publication number Publication date
EP1366158B1 (en) 2008-05-21
WO2002010382A9 (en) 2002-09-19
JP2004505617A (en) 2004-02-26
EP1366158A2 (en) 2003-12-03
WO2002010382A2 (en) 2002-02-07
US7205108B2 (en) 2007-04-17
DE60134178D1 (en) 2008-07-03
WO2002010382A3 (en) 2003-10-09
US20040072998A1 (en) 2004-04-15
ATE396266T1 (en) 2008-06-15
CA2417671A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
AU2001287639A1 (en) Trp8, trp9 and trp10, markers for cancer
HK1084691A1 (en) Modified recombinant vaccinia viruses, uses thereof
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
MXPA02002384A (en) Fibroblast growth factor like polypeptides.
ATE478952T1 (en) 36P6D5: SECRETED TUMOR PROTEIN
AU2014899A (en) Metastatic breast and colon cancer regulated genes
EP1632499A3 (en) Gene sequences amplified in tumours and their diagnostic uses
ATE407206T1 (en) METHODS OF PRODUCING GENE BANKS
DE69935220D1 (en) HUMAN TUMOR-DERIVED POLYPEPTIDEHORMONE PHOSPHATONIN
IT1298487B1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING PENTRAXIN LONG PTX3 FOR THE THERAPY OF INFECTIOUS, INFLAMMATORY OR CANCER TYPE DISEASES,
WO2000050588A3 (en) Genes associated with diseases of the colon
EP1642906A3 (en) Composition and methods for the diagnosis of tumours
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2001081577A3 (en) Dna encoding the prost 03 polypeptide
WO2001023553A3 (en) Metastasis-associated antigen c4.4a
MY127669A (en) Polypeptide hormone phosphatonin
WO2004013631A3 (en) Compositions and methods for diagnosis and therapy of cancer
DE60130541D1 (en) TISSUE-SPECIFIC PROTEIN 103P2D6, HIGHLY EXPRESSED IN DIFFERENT CANCER TYPES
WO2000020589A3 (en) PTANs: TESTIS SPECIFIC PROTEINS EXPRESSED IN PROSTATE CANCER
WO2003052377A9 (en) 41 human secreted proteins
WO1999043812A3 (en) Dlc-1 gene, a putative tumors suppressor gene
AU2001229367A1 (en) Genes differentially expressed in breast cancer
WO2004058167A3 (en) Breast specific protein expressed in cancer and methods of use thereof
WO2005062788A3 (en) Prostate specific proteins expressed in cancer and methods of use thereof
WO2005035773A8 (en) Modified cea /b7 vector